EGRX - Eagle Pharmaceuticals Inc
IEX Last Trade
5.13
-0.110 -2.144%
Share volume: 53,661
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$5.24
-0.11
-2.10%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
| Report Date | 2022-05-09 | 2022-08-09 | 2022-11-09 | 2023-03-23 | 2023-05-09 | 2023-08-08 | |
| Total revenue | 115.874 M | 74.136 M | 65.901 M | 60.699 M | 66.305 M | 64.646 M | |
| Cost of revenue | 27.755 M | 23.664 M | 23.651 M | 19.866 M | 17.300 M | 16.858 M | |
| Gross profit | 88.119 M | 50.472 M | 42.250 M | 40.833 M | 49.005 M | 47.788 M | |
| -42.72% | -16.29% | -3.35% | 20.01% | -2.48% | |||
| Operating expenses | 28.290 M | 48.269 M | 32.788 M | 31.367 M | 37.232 M | 37.484 M | |
| Selling general and admin | 22.182 M | 36.832 M | 23.462 M | 24.150 M | 27.960 M | 27.651 M | |
| Research and development | 6.108 M | 11.437 M | 9.326 M | 7.217 M | 9.272 M | 9.833 M | |
| Total expenses | 56.045 M | 71.933 M | 56.439 M | 51.233 M | 54.532 M | 54.342 M | |
| 28.35% | -21.54% | -9.22% | 6.44% | -0.35% | |||
| Operating income | 59.829 M | 2.203 M | 9.462 M | 9.466 M | 11.773 M | 10.304 M | |
| Ebit | 59.829 M | 2.203 M | 9.462 M | 9.466 M | 11.773 M | 10.304 M | |
| Pretax income | 57.660 M | -5.868 M | -3.663 M | 13.304 M | 10.231 M | 9.298 M | |
| -110.18% | -37.58% | -463.20% | -23.10% | -9.12% | |||
| Income tax | 13.602 M | 3.582 M | 3.468 M | 5.139 M | 4.481 M | 4.134 M | |
| Net income basic | 44.058 M | -9.450 M | -7.131 M | 8.165 M | 5.750 M | 5.164 M | |
| -121.45% | 24.54% | 214.50% | -29.58% | -10.19% | |||
| Net income | 44.058 M | -9.450 M | -7.131 M | 8.165 M | 5.750 M | 5.164 M | |
| -121.45% | 24.54% | 214.50% | -29.58% | -10.19% |